PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

AlzeCure’s ACD856 research shows positive impact on brain

Exploratory central nervous system analysis shows that ACD856 increases activity in the brain.

AlzeCure – a company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system – has announced that the company has received new data from its clinical phase 1 study.

The research involves the repeated dosing of drug candidate ACD856, which is being developed against Alzheimer’s disease and other indications with cognitive dysfunction.

New data from a planned exploratory analysis of the study shows that ACD856 increases activity in the brain. A clear difference can be seen after and prior to the administration of the substance. This result, combined with previously reported data, demonstrates that the substance not only crosses the blood-brain barrier but also reaches and activates neural pathways in the brain, with the potential of having positive effects on cognition.

The MAD phase 1 study is AlzeCure’s third clinical study with ACD856, the company’s leading drug candidate within the NeuroRestore platform. The substance is under development as a symptom-relieving treatment for medical conditions where cognitive ability is impaired, notably in Alzheimer’s disease.

The primary study objective was to evaluate the drug candidate’s tolerability and safety after repeated dosing. As previously reported, ACD856 shows good safety and tolerability in both the SAD and MAD studies.

ACD856 and the other substances in the NeuroRestore platform stimulate several important signalling systems in the brain such as brain-derived neurotrophic factor and nerve growth factor, which can lead to improved cognition – something that has been demonstrated in previous preclinical studies.

“This new data is very promising and show that the substance reaches and activates neural pathways in the brain, whose normal function is disrupted in diseases such as Alzheimer’s,” reflected Johan Sandin, chief scientific officer at AlzeCure Pharma.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026